News

VLEVA's EU-subsidiemonitor 2021-2022; I3, het Interregional Innovation Investment Instrument

Published on | 4 months ago

Programmes EIE

In the 'EU-subsidiemonitor 2021-2022' VLEVA investigates how Flemish organisations participate in European subsidised programs. This time with a focus for Interregional Innovation Investment Instrument - I3

  • I3 finances International cooperations building innovative value chains

  • Discover how Flanders’ FOOD with the HIGHFIVE-project stimulates digital and green growth in the agrofood-value chain in Europe.

  • Get information on the open calls in I3

Deadline for strand 1 and strand 2a are both on december 5th 2024. Recordings of the information sessions can be found here.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1530 articles available search in articles 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.